ALT - Altimmune, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.25
DETAILS
HIGH:
$20.00
LOW:
$2.50
MEDIAN:
$11.25
CONSENSUS:
$11.25
UPSIDE:
287.93%
About Altimmune, Inc. (https://altimmune.com)
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Scot Roberts | Chief Scientific Officer | 1959 | $683,229 USD |
| Gregory L. Weaver | Chief Financial Officer | 1956 | $619,694 USD |
| Raymond Jordt | Chief Business Officer | 1973 | $578,850 USD |
| Christophe Arbet-Engels | Chief Medical Officer | 1963 | $361,356 USD |
| Jerome Benedict Durso | Chairman, CEO & President | 1968 | $50,941 USD |
| Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | 1988 | – |
| Bertrand Georges | Chief Technology Officer | – | – |
| Linda Richardson | Chief Commercial Officer | 1964 | – |
| Robin E. Abrams | Chief Legal Officer & Corporate Secretary | 1964 | – |
| Tony Blandin | Vice President of Quality & Compliance Management | – | – |